Long-Term Colorectal Cancer Incidence and Mortality After Colonoscopy Screening According to Individuals' Risk Profiles
- PMID: 33734405
- PMCID: PMC8418388
- DOI: 10.1093/jnci/djab041
Long-Term Colorectal Cancer Incidence and Mortality After Colonoscopy Screening According to Individuals' Risk Profiles
Abstract
Background: It remains unknown whether the benefit of colonoscopy screening against colorectal cancer (CRC) and the optimal age to start screening differ by CRC risk profile.
Methods: Among 75 873 women and 42 875 men, we defined a CRC risk score (0-8) based on family history, aspirin, height, body mass index, smoking, physical activity, alcohol, and diet. We calculated colonoscopy screening-associated hazard ratios and absolute risk reductions (ARRs) for CRC incidence and mortality and age-specific CRC cumulative incidence according to risk score. All statistical tests were 2-sided.
Results: During a median of 26 years of follow-up, we documented 2407 CRC cases and 874 CRC deaths. Although the screening-associated hazard ratio did not vary by risk score, the ARRs in multivariable-adjusted 10-year CRC incidence more than doubled for individuals with scores 6-8 (ARR = 0.34%, 95% confidence interval [CI] = 0.26% to 0.42%) compared with 0-2 (ARR = 0.15%, 95% CI = 0.12% to 0.18%, Ptrend < .001). Similar results were found for CRC mortality (ARR = 0.22%, 95% CI = 0.21% to 0.24% vs 0.08%, 95% CI = 0.07% to 0.08%, Ptrend < .001). The ARR in mortality of distal colon and rectal cancers was fourfold higher for scores 6-8 than 0-2 (distal colon cancer: ARR = 0.08%, 95% CI = 0.07% to 0.08% vs 0.02%, 95% CI = 0.02% to 0.02%, Ptrend < .001; rectal cancer: ARR = 0.08%, 95% CI = 0.08% to 0.09% vs 0.02%, 95% CI = 0.02% to 0.03%, Ptrend < .001). When using age 45 years as the benchmark to start screening, individuals with risk scores of 0-2, 3, 4, 5, and 6-8 attained the threshold CRC risk level (10-year cumulative risk of 0.47%) at age 51 years, 48 years, 45 years, 42 years, and 38 years, respectively.
Conclusions: The absolute benefit of colonoscopy screening is more than twice higher for individuals with the highest than lowest CRC risk profile. Individuals with a high- and low-risk profile may start screening up to 6-7 years earlier and later, respectively, than the recommended age of 45 years.
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Figures
Comment in
-
Realizing the Promise of Personalized Colorectal Cancer Screening in Practice.J Natl Cancer Inst. 2021 Sep 4;113(9):1120-1122. doi: 10.1093/jnci/djab044. J Natl Cancer Inst. 2021. PMID: 33734403 Free PMC article. No abstract available.
-
RE: Long-Term Colorectal Cancer Incidence and Mortality After Colonoscopy Screening According to Individuals' Risk Profiles.J Natl Cancer Inst. 2022 May 9;114(5):779-780. doi: 10.1093/jnci/djab232. J Natl Cancer Inst. 2022. PMID: 34954798 Free PMC article. No abstract available.
-
Response to Wernly, Datz, and Wernly.J Natl Cancer Inst. 2022 May 9;114(5):781. doi: 10.1093/jnci/djab233. J Natl Cancer Inst. 2022. PMID: 34954801 Free PMC article. No abstract available.
Similar articles
-
Healthy lifestyle, endoscopic screening, and colorectal cancer incidence and mortality in the United States: A nationwide cohort study.PLoS Med. 2021 Feb 1;18(2):e1003522. doi: 10.1371/journal.pmed.1003522. eCollection 2021 Feb. PLoS Med. 2021. PMID: 33524029 Free PMC article.
-
Long-term effectiveness of faecal immunochemical test screening for proximal and distal colorectal cancers.Gut. 2021 Dec;70(12):2321-2329. doi: 10.1136/gutjnl-2020-322545. Epub 2021 Jan 25. Gut. 2021. PMID: 33495268 Free PMC article.
-
Aspirin Use and Incidence of Colorectal Cancer According to Lifestyle Risk.JAMA Oncol. 2024 Oct 1;10(10):1354-1361. doi: 10.1001/jamaoncol.2024.2503. JAMA Oncol. 2024. PMID: 39088221
-
Effectiveness of Screening Modalities in Colorectal Cancer: A Network Meta-Analysis.Clin Colorectal Cancer. 2017 Dec;16(4):252-263. doi: 10.1016/j.clcc.2017.03.018. Epub 2017 Apr 4. Clin Colorectal Cancer. 2017. PMID: 28687458 Review.
-
Options for screening for colorectal cancer.Scand J Gastroenterol Suppl. 2003;(237):13-6. doi: 10.1080/00855910310001421. Scand J Gastroenterol Suppl. 2003. PMID: 12797674 Review.
Cited by
-
Stool and blood biomarkers for colorectal cancer management: an update on screening and disease monitoring.Mol Cancer. 2024 Nov 19;23(1):259. doi: 10.1186/s12943-024-02174-w. Mol Cancer. 2024. PMID: 39558327 Free PMC article. Review.
-
Development and validation of machine learning models for young-onset colorectal cancer risk stratification.NPJ Precis Oncol. 2024 Oct 22;8(1):239. doi: 10.1038/s41698-024-00719-2. NPJ Precis Oncol. 2024. PMID: 39438621 Free PMC article.
-
Effectiveness of colorectal cancer screening integrating non-genetic and genetic risk: a prospective study based on UK Biobank data.Cancer Biol Med. 2024 Jun 20;21(8):712-23. doi: 10.20892/j.issn.2095-3941.2024.0096. Cancer Biol Med. 2024. PMID: 38899940 Free PMC article.
-
Optimal timing of a colonoscopy screening schedule depends on adenoma detection, adenoma risk, adherence to screening and the screening objective: A microsimulation study.PLoS One. 2024 May 24;19(5):e0304374. doi: 10.1371/journal.pone.0304374. eCollection 2024. PLoS One. 2024. PMID: 38787836 Free PMC article.
-
External validation of the colorectal cancer risk score LiFeCRC using food frequency questions in the HUNT study.Int J Colorectal Dis. 2024 Apr 25;39(1):57. doi: 10.1007/s00384-024-04629-4. Int J Colorectal Dis. 2024. PMID: 38662227 Free PMC article.
References
-
- Siegel RL, Miller KD, Jemal A.. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30. - PubMed
-
- Baxter NN, Goldwasser MA, Paszat LF, et al.Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009;150(1):1–8. - PubMed
-
- Atkin WS, Edwards R, Kralj-Hans I, et al.; UK Flexible Sigmoidoscopy Trial Investigators. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375(9726):1624–1633. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
